BNS808
BNS808 is an orally active and selective cannabinoid-1 receptor (CB1R) antagonist (IC50 = 0.8 nM) with notable CB2R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD) . BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding[1].
Product Specifications
CAS Number
2836313-12-1
UNSPSC
12352101
Target
Cannabinoid Receptor; Cytochrome P450
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Smiles
ClC1=CC=C(S(=O)(NC2CCCOC3=C(C4=CC=C(Cl)C=C4)N(C5=C(Cl)C=CC=C5)N=C23)=O)C=C1
Molecular Formula
C25H20Cl3N3O3S
Molecular Weight
548.87
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CB1; CYP1; CYP2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
